Navigation Links
Castle Biosciences Launches Tissue Repository for Eye Cancer Patients
Date:9/30/2013

tment advances requiring tumor analysis, a rapidly expanding area of oncology research about which OMF is extremely excited."

"Patients who have chosen to undergo DecisionDx-UM already know the importance of genetic testing in the management and follow-up care of their disease," said Derek Maetzold, CEO of Castle Biosciences. "We believe it is important to offer this new tissue repository service which will expand patient and physician access to future testing."

For more information, please visit www.MyUvealMelanoma.com

About Uveal Melanoma
Although it is rare, and its cause not well understood, uveal melanoma is the most common form of eye cancer in the United States, with about 2,000 diagnoses per year. This form of eye cancer, sometimes referred to as ocular melanoma, may occur in any of the three parts of the uvea. For this reason, it is sometimes referred to as choroidal, ciliary body, or iris melanoma based upon its exact location. The choroid is the most common place for a tumor to develop.

Similar to other melanomas, uveal melanoma begins in cells called melanocytes that help produce the pigments of the skin, hair, and eyes. While most patients are middle-aged with fair skin, uveal melanoma can and has affected people of all complexions and ages. Treatments for the primary uveal melanoma tumors are highly effective; however, there is currently no cure for metastatic disease.

About DecisionDx-UM
The DecisionDx-UM test measures the gene expression profile (GEP), or molecular signature, of an individual's tumor and identifies with high accuracy the likelihood of metastasis. The test requires a sample of the patient's tumor that is obtained prior to radiation surgery, the most common therapy used in the treatment of uveal melanoma.

The DecisionDx-UM test is standard of care in the management of uveal melanoma in
'/>"/>

SOURCE Castle Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem Cell Therapy
2. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. MD Biosciences Publishes the Characterization of a Porcine Model of Post-operative Or Incisional Pain in the European Journal of Pain
5. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
6. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
7. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
8. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
9. Sangamo BioSciences Proposes Public Offering Of Common Stock
10. Rancho BioSciences Partners with OmicSoft for Manual Data Curation
11. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... BATON ROUGE, La. , June 1, 2015 /PRNewswire/ ... a Phase II trial of lead candidate EP-100 in ... targeted membrane-disrupting peptide designed to seek and destroy cancer ... their surfaces. LHRH receptors are over-expressed in a wide ... randomized, multi-center Phase II trial of EP-100 ...
(Date:6/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: ... the Jefferies 2015 Global Healthcare Conference in ... 2015. Jeff Poulton , Chief Financial Officer will ... a.m. ET (3:00 p.m. BST). A live ... Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx ...
(Date:6/1/2015)... 1, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced positive, new, ... trial of AST-VAC1 in patients with intermediate and ... the Company,s autologous (using cells sourced from the ... the most common form of acute leukemia in ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... BEIJING, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Yongye International,Inc. (Nasdaq: ... manufacturer,developer and distributor of Shengmingsu brand plant and animal ... announced its 2010-,2012 strategic plan. , ... and thus far in,2009, Yongye expects to achieve at ...
... ... with the addition of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) ... Situational Leadership V (SLV) series specifically for biotech and specialty pharma companies. The new ...
... LAFAYETTE, Ind. - Researchers have overcome a major obstacle ... to create a new class of electronics that would ... Carbon nanotubes, which were discovered in the early 1990s, ... as well as ultra-thin "nanowires" for electronic circuits. The ...
Cached Biology Technology:Yongye International Announces 2010-2012 Strategic Plan 2Yongye International Announces 2010-2012 Strategic Plan 3Yongye International Announces 2010-2012 Strategic Plan 4Yongye International Announces 2010-2012 Strategic Plan 5Perceptum Group Announces New Situational Leadership V Series 2Better control of carbon nanotube 'growth' promising for future electronics 2Better control of carbon nanotube 'growth' promising for future electronics 3
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... patient,s body, stem cells intended to treat or cure ... they are no longer under the control of the ... solve this problem, according to a perspective article from ... a recent issue of the journal Cell Stem ...
... traffic lights the scourge of Britain,s roads! But now ... misery of motorists caused by the repair, maintenance and ... reveal how new technology will allow workers to virtually ... seminar at The University of Nottingham on June 11th ...
... popular belief, aggressive dogs are NOT trying to assert ... to research published by academics at the University of ... Journal of Veterinary Behavior, Clinical Applications and Research . ... interacting at a Dogs Trust rehoming centre, and reanalysing ...
Cached Biology News:Gene therapy could expand stem cells' promise 2Reducing the roadworks 2Reducing the roadworks 3Using 'dominance' to explain dog behavior is old hat 2
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Biology Products: